相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Visualization and quantification of protein-protein interactions in cells and tissues
Mats Gullberg et al.
NATURE METHODS (2018)
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors
Taekyu Lee et al.
FEBS LETTERS (2017)
Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Michelle M. Williams et al.
MOLECULAR CANCER RESEARCH (2017)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
Grace R. Anderson et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia
Rongqing Pan et al.
BLOOD (2015)
MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Yu Xiao et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
Anthony C. Faber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
J. D. Leverson et al.
CELL DEATH & DISEASE (2015)
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells
S. Thrane et al.
ONCOGENE (2015)
Estrogen Regulation of Anti-Apoptotic Bcl-2 Family Member Mcl-1 Expression in Breast Cancer Cells
Jennifer L. Schacter et al.
PLOS ONE (2014)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
Anthony C. Faber et al.
CANCER DISCOVERY (2014)
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Francois Vaillant et al.
CANCER CELL (2013)
BCL-2: A New Therapeutic Target in Estrogen Receptor-Positive Breast Cancer?
Lesley-Ann Martin et al.
CANCER CELL (2013)
Mcl1 regulates the terminal mitosis of neural precursor cells in the mammalian brain through p27Kip1
S. M. Mahmudul Hasan et al.
DEVELOPMENT (2013)
Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
Xi Wang et al.
GENES & DEVELOPMENT (2013)
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens
Meghan M. Morrison et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Mcl-1 is essential for the survival of plasma cells
Victor Peperzak et al.
NATURE IMMUNOLOGY (2013)
Pathologic Changes in Breast Cancer After Anti-Estrogen Therapy
Norasate Samarnthai et al.
BREAST JOURNAL (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Samantha R. Oakes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer
Suleiman Massarweh et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Novel Mechanism of Anti-apoptotic Function of 78-kDa Glucose-regulated Protein (GRP78) ENDOCRINE RESISTANCE FACTOR IN BREAST CANCER, THROUGH RELEASE OF B-CELL LYMPHOMA 2 (BCL-2) FROM BCL-2-INTERACTING KILLER (BIK)
Hui Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Mitochondria and cell death: outer membrane permeabilization and beyond
Stephen W. G. Tait et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis
Anatasha C. Crawford et al.
PLOS ONE (2010)
Nanoparticle-based targeted drug delivery
Rajesh Singh et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
Suleiman Massarweh et al.
CANCER RESEARCH (2008)
The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages
Ivan Dzhagalov et al.
JOURNAL OF IMMUNOLOGY (2008)
Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage
Nicole Arbour et al.
JOURNAL OF NEUROSCIENCE (2008)
Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3β activity and associates with poor prognosis in human breast cancer
Qingqing Ding et al.
CANCER RESEARCH (2007)
Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities
Suleiman Massarweh et al.
CLINICAL CANCER RESEARCH (2007)
The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages
Ivan Dzhagalov et al.
BLOOD (2007)
Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein
Jingyung Hur et al.
CANCER RESEARCH (2006)
Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario
J. E. Chipuk et al.
CELL DEATH AND DIFFERENTIATION (2006)
Exploiting the enhanced permeability and retention effect for tumor targeting
Arun K. Iyer et al.
DRUG DISCOVERY TODAY (2006)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis
JY Hur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells
PJ Real et al.
ONCOGENE (2002)
BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis
EHYA Cheng et al.
MOLECULAR CELL (2001)
分享论文
